The global burden of diabetic nephropathy increased from 1990 to 2021, and is projected to continue increasing to 2050, ...

People with cardiometabolic disorders—such as obesity, diabetes and heart disease—could increase their chances of living longer by adopting a healthy plant-based diet, according to a study being ...

We recently published a list of 10 Best Diabetes Stocks To Buy According to Billionaires. In this article, we are going to ...

The global burden of diabetic nephropathy increased from 1990 to 2021, and is projected to continue increasing to 2050, ...

The development is set to make India less reliant on China for imports of raw material used by the pharmaceutical industry.

Making the dragon and elephant dance is the only right choice,” says China’s Foreign Minister Wang Yi as he extends a friendly hand to India to bolster the democratisation of global relations while ...

At a recent news conference, Lei Haichao, head of the National Health Commission (NHC), announced plans to establish more ...

Doctors give acupuncture treatment to patients who want to lose weight at Zhejiang Provincial Hospital of Traditional Chinese ...

The weight management clinic at Jincheng People's Hospital was established in 2023, and this week, it was expanded into a ...

Novo Nordisk's GLP-1 agonist Ozempic (semaglutide) has been available in China for diabetes since 2021, and the Wegovy formulation for obesity got the green light from the NMPA last month.

China represents an untapped market for GLP-1 class diabetes drugs, according to Novo Nordisk, which is predicting "good momentum" for its already-approved Victoza, and its successor semaglutide.

IST, the barometer index, the S&P BSE Sensex, advanced 500.29 points or 0.68% to 74,682.80. The Nifty 50 index jumped 137.85 points or 0.61% to 22,646.60.